Citeline Podcasts

In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market analysis across Europe and US, as well as growing therapeutics area trends within biotech.

Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.

Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb (MedTech Insight) speaks with Dr. Soeren Mattke, research professor of economics at USC, director of the Brain Health Observatory, and member of the scientific advisory board of ALZpath, about how FDA-cleared blood tests are changing the picture.

They cover why amyloid PET scans and spinal taps struggle to scale, how p-tau217 blood tests work and who makes them, and how primary care doctors can use them to prioritize patients and better prepare referrals to overstretched neurologists. They also discuss test limitations, including false positives and the potential of misdiagnosis when patients have other diseases like kidney disease and obesity, why screening people without symptoms isn’t recommended yet, and the economics: roughly $5,000 for a PET scan versus about $125 for a Medicare-reimbursed blood test.

Follow the In Vivo podcast on Apple Podcasts and Spotify to stay ahead of what’s shaping life sciences next.

In the latest episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the reasons Iilun Murphy, director of the US Food and Drug Administration’s Office of Generic Drugs, decided to step down (:53) and whether the move should concern senior agency officials (2:51). They also consider the FDA’s plan to create a fit-for-purpose rare disease approval framework (12:19), how it will connect with the agency’s litany of programs for the products (14:52) and the potential difficulties of systematizing regulatory flexibility (18:22).

More On These Topics From The Pink Sheet

US FDA Generic Drugs Office Director Steps Down Amid ‘Political Pressure,’ Admin Burden: https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/us-fda-generic-drugs-office-director-steps-down-amid-political-pressure-admin-burden-RSIU23LDWZETDO5XYPAAPCIKVM/

US FDA’s Rare Disease Framework Envisions Systematic Regulatory Flexibility: https://insights.citeline.com/pink-sheet/rare-diseases/us-fdas-rare-disease-framework-envisions-systematic-regulatory-flexibility-CKPMVFWBEVF3DNERAJBZZ23EYA/

US FDA Eyes Adaptive Rare Disease Framework To Replace Piecemeal Flexibilities: https://insights.citeline.com/pink-sheet/rare-diseases/us-fda-eyes-adaptive-rare-disease-framework-to-replace-piecemeal-flexibilities-JU2IHKV76ZHYXDZQBW23BE3FRI/

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ZCXOSRSNEBCARAW4DUWENVCPSQ/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。Feedback: [email protected]

In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-use device; George Underwood, Reset Health’s GLP-1 adherence data; and Marion Webb, Hillary Lin’s evidence-based longevity care;

Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended Oct. 9, 2026. This time—China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s $2bn acquisition. 

This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcastsand on TuneIn.

Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it takes to commercialize a topical dermatology drug in an increasingly scrutinized promotional environment.​​

Commercial strategies, ad campaigns, dermatology

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Senior Reporter Maaisha Osman discuss the drama unfolding at the US Food and Drug Administration related to a Health and Human Services Department plan to temporarily allow some compounding of unapproved peptides (:52).

They also consider the impact of the FDA’s intent to acknowledge individual NDA and BLA filings (13:00) and whether the policy will have to endure legal challenges (26:48), as well as the potential clinical trial requirements for the psychedelic ibogaine and their potential impact on product development (28:27).

More On These Topics From The Pink Sheet

US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order: ⁠https://insights.citeline.com/pink-sheet/product-reviews/approvals/us-fda-staff-push-back-against-trump-administration-interim-peptide-dispensing-order-KE3EBXDBNBDKBJBSOBF772HUAY/⁠

Transparency Growing: US FDA Plans Reg Allowing NDA, BLA Filing Disclosure: ⁠https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/transparency-growing-us-fda-plans-reg-allowing-nda-bla-filing-disclosure-5OR6R4R54VFWRBCUKXJOSVMXZQ/⁠

US FDA Signals Cardiac Safety Monitoring Will Be Ibogaine’s Regulatory Hurdle: ⁠https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/us-fda-signals-cardiac-safety-monitoring-will-be-ibogaines-regulatory-hurdle-LGD2YI6EW5GPLBWHUDM3FMUIT4/